Sun, Sep 21, 2014, 1:14 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, Inc. (OPTR) Message Board

  • tedkov tedkov Jul 30, 2013 7:30 PM Flag

    BUYOUT OF OPTIMER - LAW FIRM SEEKS HIGHER PRICE FOR SHAREHOLDERS

     

    NEW YORK--
    Tripp Levy PLLC, a leading national securities and shareholder rights law firm is investigating the Board of Directors of Optimer Pharmaceuticals, Inc. (“Optimer” or the “Company”) (OPTR) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Cubist Pharmaceuticals, Inc.

    Under the terms of the transaction, Optimer shareholders will receive $10.75 in cash for each share of Optimer stock they own. Optimer shareholders will also receive a Contingent Value Right entitling them to receive up to $5.00 for each share they own if certain net sales of the drug DIFICID are achieved. The investigation concerns whether the Optimer Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Cubist Pharmaceuticals, Inc. is underpaying for Optimer shares. In particular, at least one analyst set a price target of $25.00 per Optimer share.
    If you own common stock in Optimer and wish to obtain additional information or discuss your rights, please contact us at 1-877-772-3975 or email at contact @ tripplevy

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
OPTR
12.780.00(0.00%)Oct 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.